Latest Pharma and Biotech News
Pharmaceutical
13 January 2026 The Biotechnology Innovation Organization criticized changes to the US childhood immunization schedule, saying the move lacks a scientific basis and could put children’s health at risk.
Today's issue
Refine Search
Pharmaceutical
US rare disease specialist Sentynl Therapeutics, owned by India’s Zydus Lifesciences, says the US regulator has accepted the resubmission of its New Drug Application for Zycubo (copper histidinate), previously known as CUTX-101, for pediatric Menkes disease. 13 January 2026
Biotechnology
Taiwan-based PharmaEssentia Corporation, a biopharma seeking to deliver new biologics in hematology and oncology, has announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for ropeginterferon alfa-2b-njft for the treatment of adult patients with essential thrombocythemia (ET). 13 January 2026
Biotechnology
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
Pharmaceutical
Germany’s Merck KGaA has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). 13 January 2026
Biotechnology
UK-based Nuclera, a biotech accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, has announced a $12 million financing extension, bringing the company’s total Series C funding to $87 million. 13 January 2026
Biotechnology
UK-based Qureight, a tech-bio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as chief operating officer (COO). 13 January 2026
Pharmaceutical
US pharma major AbbVie plans to acquire a drug delivery device manufacturing facility in Tempe, Arizona, as part of its $10 billion pledge to expand US operations through 2035. The site will be bought from West Pharmaceutical Services and is expected to close by mid-2026. 13 January 2026
Pharmaceutical
The Biotechnology Innovation Organization criticized changes to the US childhood immunization schedule, saying the move lacks a scientific basis and could put children’s health at risk. 13 January 2026
Pharmaceutical
Efforts to return to growth in UK clinical trials are gathering pace, with new figures showing a sharp rise in activity in 2025. 13 January 2026
Biotechnology
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational programmed cell death-1 (PD-1)/V7 vascular endothelial growth Factor (VEGF)-targeted bispecific antibody. 12 January 2026
Biotechnology
Dewpoint Therapeutics, a US biotech developing condensate-modulating therapeutics, has announced the selection of a development candidate (DC) for its TDP-43 program. 12 January 2026
Biotechnology
The European Commission has approved French pharma major Sanofi’s Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and older with stage 2 T1D. 12 January 2026
Pharmaceutical
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) prolonged-release tablets, two differentiated treatments designed to meet the diverse needs of children and adolescents living with attention deficit and hyperactivity disorder (ADHD). 12 January 2026
Biotechnology
The US Food and Drug Administration (FDA) has released information on what it calls its flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT). 12 January 2026
Biotechnology
US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios, at the JP Morgan conference. 12 January 2026
Biotechnology
US biopharma Eikon Therapeutics plans to go public via an IPO on the Nasdaq, following in the footsteps of Aktis Oncology—biotech’s first public debut of 2026. 12 January 2026
Biotechnology
San Francisco, USA-based Chai Discovery, the AI company building a computer-aided design suite for molecules, has announced a collaboration with pharma major Eli Lilly to accelerate biologics discovery using artificial intelligence. 12 January 2026
Pharmaceutical
Swiss biotech startup FluoSphera has raised 1.23 million euros ($1.34 million) to expand commercial activity and advance its AI-driven imaging platform for preclinical drug testing. The funding round was led by Soulmates Ventures, with participation from a Swiss business angel and IndieBio New York. 12 January 2026
Pharmaceutical
Europe is in danger of falling behind in the development of innovative medicines, according to Dutch pharma trade group VIG chairman Mark Kramer in a BNR Nieuwsradio segment, who noted that, "due to shifting global boundaries, Europe is losing importance. You need a complete ecosystem for innovation to flourish." 12 January 2026
Pharmaceutical
US radiopharma newcomer Aktis Oncology raised about $318 million after pricing an upsized initial public offering at the top of its range, becoming the first biotech company to list publicly in 2026 after a prolonged market freeze. 12 January 2026
All news
Pharmaceutical
US rare disease specialist Sentynl Therapeutics, owned by India’s Zydus Lifesciences, says the US regulator has accepted the resubmission of its New Drug Application for Zycubo (copper histidinate), previously known as CUTX-101, for pediatric Menkes disease. 13 January 2026
Biotechnology
Taiwan-based PharmaEssentia Corporation, a biopharma seeking to deliver new biologics in hematology and oncology, has announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for ropeginterferon alfa-2b-njft for the treatment of adult patients with essential thrombocythemia (ET). 13 January 2026
Biotechnology
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
Pharmaceutical
Germany’s Merck KGaA has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). 13 January 2026
Biotechnology
UK-based Nuclera, a biotech accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, has announced a $12 million financing extension, bringing the company’s total Series C funding to $87 million. 13 January 2026
Biotechnology
UK-based Qureight, a tech-bio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as chief operating officer (COO). 13 January 2026
Pharmaceutical
US pharma major AbbVie plans to acquire a drug delivery device manufacturing facility in Tempe, Arizona, as part of its $10 billion pledge to expand US operations through 2035. The site will be bought from West Pharmaceutical Services and is expected to close by mid-2026. 13 January 2026
Pharmaceutical
The Biotechnology Innovation Organization criticized changes to the US childhood immunization schedule, saying the move lacks a scientific basis and could put children’s health at risk. 13 January 2026
Pharmaceutical
Efforts to return to growth in UK clinical trials are gathering pace, with new figures showing a sharp rise in activity in 2025. 13 January 2026
Biotechnology
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational programmed cell death-1 (PD-1)/V7 vascular endothelial growth Factor (VEGF)-targeted bispecific antibody. 12 January 2026
Biotechnology
Dewpoint Therapeutics, a US biotech developing condensate-modulating therapeutics, has announced the selection of a development candidate (DC) for its TDP-43 program. 12 January 2026
Biotechnology
The European Commission has approved French pharma major Sanofi’s Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and older with stage 2 T1D. 12 January 2026
Pharmaceutical
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) prolonged-release tablets, two differentiated treatments designed to meet the diverse needs of children and adolescents living with attention deficit and hyperactivity disorder (ADHD). 12 January 2026
Biotechnology
The US Food and Drug Administration (FDA) has released information on what it calls its flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT). 12 January 2026
Biotechnology
US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios, at the JP Morgan conference. 12 January 2026
Biotechnology
US biopharma Eikon Therapeutics plans to go public via an IPO on the Nasdaq, following in the footsteps of Aktis Oncology—biotech’s first public debut of 2026. 12 January 2026
Biotechnology
San Francisco, USA-based Chai Discovery, the AI company building a computer-aided design suite for molecules, has announced a collaboration with pharma major Eli Lilly to accelerate biologics discovery using artificial intelligence. 12 January 2026
Pharmaceutical
Swiss biotech startup FluoSphera has raised 1.23 million euros ($1.34 million) to expand commercial activity and advance its AI-driven imaging platform for preclinical drug testing. The funding round was led by Soulmates Ventures, with participation from a Swiss business angel and IndieBio New York. 12 January 2026
Pharmaceutical
Europe is in danger of falling behind in the development of innovative medicines, according to Dutch pharma trade group VIG chairman Mark Kramer in a BNR Nieuwsradio segment, who noted that, "due to shifting global boundaries, Europe is losing importance. You need a complete ecosystem for innovation to flourish." 12 January 2026
Pharmaceutical
US radiopharma newcomer Aktis Oncology raised about $318 million after pricing an upsized initial public offering at the top of its range, becoming the first biotech company to list publicly in 2026 after a prolonged market freeze. 12 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A European specialty pharmaceutical company focused on central nervous system disorders. The group operates with major hubs in Spain and Germany and maintains a commercial footprint across multiple European markets, supported by a mix of direct affiliates and partner distribution in selected territories.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze